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Abstract
Nicotine has been proposed to be a cognitive enhancer, particularly in schizophrenia patients. So far, the pub-
lished studies of nicotine eﬀects on antisaccade performance in schizophrenia patients only tested participants
who were deprived smokers. Thus, we aimed to test both smoking and non-smoking patients as well as healthy
controls in order to extend previous ﬁndings. Moreover, we employed a paradigm using standard and delayed
trials. We hypothesized that, if nicotine is a genuine cognitive enhancer, its administration would improve
antisaccade performance both in smoking and non-smoking participants. A total of 22 patients with schizo-
phrenia (12 smokers and 10 non-smokers) and 26 controls (14 smokers and 12 non-smokers) completed the
study. The eﬀects of a nicotine patch (14 mg for smokers, 7 mg for non-smokers) on antisaccade performance
were tested in a randomized, double-blind, placebo-controlled, cross-over trial. Schizophrenia patients made
signiﬁcantly more antisaccade errors than controls (p=0.03). Both patients and controls made fewer antisaccade
errors in the delayed trials than in the standard trials (p<0.0001). Nicotine signiﬁcantly reduced antisaccade
error rate in the standard trials, but not in the delayed trials (p=0.02). Smoking status did not inﬂuence the
nicotine eﬀect on antisaccade error rate (p=0.10) indicating an equal procognitive eﬀect of nicotine in smokers
and non-smokers. Overall the present ﬁndings indicate that beneﬁcial eﬀects of nicotine on antisaccade per-
formance are not conﬁned to smoking schizophrenia patients. Instead, the ﬁndings likely represent genuine
nicotine-induced enhancement of cognitive performance.
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Introduction
The antisaccade task (Hallett 1978) represents a relatively
simple paradigm, which serves as a model system for an
important aspect of executive control (Reuter and
Kathmann, 2004 ; Hutton and Ettinger, 2006). This task
demands the inhibition of an automatic, phylogenetically
old and ontogenetically over-learned saccade towards a
peripheral stimulus ; instead, the participant has to in-
itiate a voluntary eye movement to the mirror image
location of the stimulus. The ability to control behaviour
ﬂexibly, responding automatically to stimuli in one situ-
ation and suppressing this automatic response in favour
of an alternative response in a diﬀerent situation, is one of
the key components of executive control. Patients with
schizophrenia, their unaﬀected-ﬁrst degree relatives and
individuals with schizophrenia spectrum disorders ex-
hibit impaired antisaccade performance reﬂected by in-
creased antisaccade error rates, increased antisaccade
latencies and also inaccurate antisaccade amplitudes
(i.e. impaired antisaccade spatial gain ; Clementz et al.,
1994 ; Ross et al., 1998 ; McDowell et al., 1999; Ettinger
et al., 2004, 2006 ; Maccabe et al., 2005; Hutton and
Ettinger, 2006; Nieman et al., 2007 ; Petrovsky et al., 2009).
Two antisaccade studies with schizophrenia patients
employed a delayed antisaccade paradigm in addition
to the commonly used standard paradigm (Reuter et al.,
2005, 2007) : in those studies the participants performed
antisaccade tasks that required the execution of a
voluntary saccade immediately after the onset of a per-
ipheral visual stimulus (standard antisaccades) or after
a brief delay (delayed antisaccades). In the delayed
condition, participants have to continue to ﬁxate on
a central stimulus until they are prompted to perform
the antisaccade. One of the main ﬁndings in both
studies was that, regardless of condition, schizophrenia
patients made more antisaccade errors than controls.
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Furthermore, antisaccade error rate was reduced in the
delay conditions compared to the standard condition
(Reuter et al., 2005, 2007). Thus, the results of Reuter et al.
(2005, 2007) suggest that schizophrenia patients may
have a speciﬁc deﬁcit in initiating voluntary saccades and
that this deﬁcit is at least in part responsible for the anti-
saccade deﬁcit.
It has been shown previously that antisaccade per-
formance is sensitive to cholinergic manipulation.
Nicotine enhanced antisaccade performance in studies
with schizophrenia patients (Depatie et al., 2002;
Larrison-Faucher et al., 2004) and in healthy participants
(Depatie et al., 2002 ; Rycroft et al., 2006, 2007; Dawkins
et al., 2007 ; Ettinger et al., 2009 ; Bowling and Donnelly,
2010 ; Petrovsky et al., 2012), while the anticholinergic
substance procyclidine worsened antisaccade perform-
ance in schizophrenia patients (Ettinger et al., 2003). In
addition, varenicline [a relatively speciﬁc a4b2 nicotinic
acetylcholine receptor (nAChR) agonist] improved anti-
saccade performance in schizophrenia patients in a recent
clinical trial (Hong et al., 2011). However, the only two
published studies of nicotine eﬀects on antisaccade per-
formance in schizophrenia patients (Depatie et al., 2002;
Larrison-Faucher et al., 2004) tested deprived smokers.
Methodologically, testing deprived smokers is not opti-
mal, because it is diﬃcult to determine whether per-
formance-enhancing eﬀects of nicotine represent genuine
enhancement or simply a relief-from-withdrawal
phenomenon (Heishman et al., 2010).
It remains to be elucidated by which mechanisms nic-
otine exerts its beneﬁcial eﬀects on antisaccade perform-
ance. A paradigm involving standard and delayed
antisaccades might at least disentangle two components
of antisaccade performance : inhibition and voluntary
saccade generation. In standard trials both inhibition of a
reﬂexive saccade and volitional saccade generation are
required simultaneously, whereas in delayed trials inhi-
bition is facilitated due to elongated ﬁxation and saccade
generation is required after the temporal delay.
Assuming that nicotine enhances inhibitory processes
(possibly via higher order cognitive functions such as
strengthened working memory representations support-
ing goal-directed activity ; Rycroft et al., 2007), we would
expect that nicotine would be more beneﬁcial in standard
antisaccade trials than in delayed trials.
In the present study, therefore, we aimed at testing the
eﬀects of nicotine on antisaccade performance both in
deprived smokers and in non-smokers with and without
schizophrenia in order to : (1) replicate the ﬁndings on
nicotine in deprived smokers with schizophrenia ; (2) ex-
tend the design to non-smoking schizophrenia patients.
A performance-enhancing eﬀect of nicotine only in de-
prived smokers would imply a relief-from-withdrawal
phenomenon, whereas an equal performance-enhancing
eﬀect of nicotine both in smokers and non-smokers
would indicate genuine performance enhancement by
nicotine instead of simple relief-from-withdrawal. Thus,
the combined assessment of samples of smokers and non-
smokers oﬀers the advantage of distinguishing between
withdrawal relief and cognitive enhancement. Moreover,
we used the variation of the antisaccade task as employed
by Reuter et al. (2005, 2007) in order to investigate nic-
otine eﬀects in standard antisaccades and delayed anti-
saccades.
Thus, we hypothesized: (1) patients with schizo-
phrenia will exhibit worse antisaccade performance than
controls ; (2) antisaccade errors will be less frequent in the
delayed antisaccade task than in the standard task ; (3)
nicotine administration will improve antisaccade per-
formance both in smoking and non-smoking partici-
pants ; (4) nicotine will improve standard antisaccades
to a greater extent than delayed antisaccades.
Method and materials
Participants
Male and female participants, smokers as well as non-
smokers, aged 18–55 yr were included in the present
study. Patients with a diagnosis of either ‘schizophrenia,
paranoid type’ (DSM-IV 295.3) or of ‘schizo-aﬀective
disorder’ (DSM-IV 295.7) were included. Participants
with psychosis were recruited from the out-patient clinic
of the University Hospital, Bonn. Control participants
were recruited from the local community by advertise-
ment and by contacting a random sample of the in-
habitants of Bonn based on a list from the city registry.
For control participants it was a requirement that they
did not have a relative with a history of psychosis (i.e.
schizophrenia, schizo-aﬀective disorder, bipolar dis-
order) up to the third degree of kinship. All participants
were interviewed with the German version of the
Structured Clinical Interview (SCID-I) for DSM-IV
(Wittchen et al., 1997). SCID-I veriﬁed diagnosis in pa-
tients with psychosis and ensured control participants
were free from a current or lifetime Axis I disorder. In
patients, current symptoms were rated using the Positive
and Negative Syndrome Scale (PANSS; Kay et al., 1987)
and the Calgary Depression Scale for Schizophrenia
(Muller et al., 1999). Non-smoking participants were de-
ﬁned as individuals who had smoked f100 cigarettes
during their lifetime (Schoenborn et al., 2003). Verbal IQ
of all participants was estimated with a standardized
German vocabulary test, the Mehrfachwahl-Wortschatz-
Intelligenztest-B (Lehrl, 1989).
Exclusion criteria were : head injury with loss of con-
sciousness >5 min; lifetime history of alcohol or sub-
stance abuse or dependence ; history of neurological
illness or another severe medical condition. Additional
exclusion criteria for patients were : clinical instability ;
recent change in medication (<6 wk) ; anticholinergic
medication. Further exclusion criteria were severe obesity
(BMI >35 kg/m2) and uncorrected visual impairments.
Furthermore, the following exclusion criteria were
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employed in order to avoid serious side-eﬀects caused by
the nicotine application : cardiovascular disease ; hyper-
tension; atopic or eczematous dermatitis (due to localized
patch sensitivity) ; severe renal or hepatic impairment or
active peptic ulcers ; hyperthyroidism; pheochromocyto-
ma; insulin-dependent diabetes ; hypersensitivity to
patches ; hypersensitivity to nicotine or any of the in-
gredients of the patches. A study physician ensured that
all inclusion and exclusion criteria were met. Approval
of the local ethics committee and the German Federal
Institute for Drugs and Medical Devices was obtained
and the study was registered with http://www.clinical
trials.gov (ClinicalTrials.gov Identiﬁer : NCT01315002).
Participants provided written informed consent before
inclusion. All participants were compensated for their
participation.
Procedures
On both testing days, a urine drug screening test (nal von
minden, Germany) was applied before patch application
to ensure participants had abstained from amphetamine,
benzodiazepine, cocaine, THC cannabinoides and opiate/
morphine. All female participants additionally under-
went a urine pregnancy test (Hitado hCG; Hitado Direkt,
Germany) on both testing days to conﬁrm they were not
pregnant. In smokers, smoking abstinence (12 h before
patch application) was veriﬁed by measuring breath
carbon monoxide (<10 ppm).
Nicotine was administered in a randomized, double-
blind, placebo-controlled, cross-over design. Each par-
ticipant completed two oculomotor testing sessions (one
nicotine session and one placebo session; the order of
sessions was counterbalanced). Nicotine was applied via
patches (NiQuitin Clear ; GlaxoSmithKline, UK; 7 mg
patch for non-smoking participants, 14 mg patch for
smoking participants). The nicotine dosages were chosen
in accordance with previously published studies which
found cognitive eﬀects of nicotine in the absence of sig-
niﬁcant side-eﬀects (Levin et al., 1998 ; Depatie et al.,
2002 ; Poltavski and Petros, 2006 ; Petrovsky et al., 2012).
Placebo patches (Fink and Walter GmbH, Germany) of
similar appearance were applied. Both patches were ap-
plied non-visibly to the upper back of the participant by a
research assistant who was not running the test sessions,
in order to ensure double-blindness. Oculomotor testing
commenced 3 h after patch application. Nicotine admin-
istration using the NiQuitin patch generates a fast-rising
nicotine plasma level (a nicotine plateau level is achieved
2–4 h after application according to the summary of
product characteristics of NiQuitin Clear).
Cotinine plasma levels
Blood samples were collected in anticoagulant EDTA
9 ml tubes and centrifuged for 10 min with a centrifugal
force of 1610 g. Plasma was collected, allotted to two ali-
quots and frozen atx80 xC in order to be later analysed
for cotinine. Cotinine was quantiﬁed with liquid chro-
matography–mass spectrometry, a highly speciﬁc and
sensitive method (Gabr et al., 2011).
Saccadic tasks
Participants were seated 41 cm from a 17-inch monitor ;
head movements were minimized using a chinrest. The
testing room was quiet and dimly lit. Experimental
stimuli were presented using ERTS1 (BeriSoft Corpor-
ation, Germany). Participants performed one block of in-
termixed standard and delayed prosaccade trials and one
block of intermixed standard and delayed antisaccade
trials. The order was ﬁxed beginning with the block of
prosaccades.
A standard trial (i.e. a trial with no delay) started with
the ﬁxation of a central white cross on a black back-
ground for the duration of 1000, 1500, 2000 or 2500 ms at
random. Subsequently, a 440 Hz sine wave tone (50 ms)
and a peripheral target dot (1000 ms) were presented
simultaneously. The target dot randomly appeared at
¡6x or ¡12x eccentricity. All stimuli were extinguished
1800 ms after dot and tone onset. A new trial started after
1300 ms.
A delayed trial started with the ﬁxation of a central
white cross on a black background for the duration of
1000, 1500, 2000 or 2500 ms at random. The ﬁxation cross
remained on the screen after the appearance of a periph-
eral target dot. The target dot randomly appeared at¡6x
or ¡12x eccentricity. After a delay of 800, 1000 or
1200 ms, a 440 Hz sine wave tone was presented for
50 ms while both ﬁxation cross and peripheral target re-
mained on for the remainder of the trial. A new trial
commenced after 1300 ms.
The participant was instructed to ﬁxate the central
cross and to look towards the peripheral target dot as
quickly and as accurately as possible whenever the tone
was presented (prosaccade trials), or to look to the mirror
position of the target dot as quickly and as accurately as
possible whenever the tone was presented (antisaccade
trials).
Altogether there were 144 trials (72 prosaccade and 72
antisaccade trials). The sequence of peripheral target
presentations was pseudo-randomized. There were ﬁve
practice trials before each block which were not included
in the analysis.
Eye movement recording and analysis
Eye movements were recorded using electro-
oculography. Eye movement recording and analysis have
been described in detail elsewhere (Petrovsky et al.,
2012). The dependent variables were latencies of pro- and
antisaccade trials (time between tone appearance and
saccade initiation of correct trials) and percentage anti-
saccade errors (the ﬁrst saccade after appearance of the
peripheral target was performed towards the target). The
antisaccade error rate is calculated as the percentage
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of error trials over the total number of valid saccade trials
(excluding e.g. eye-blink trials).
Statistical analyses
Statistical analyses were conducted using the software
PASW Statistics 18 (SPSS Inc., USA). For the statistical
analysis of nicotine eﬀects on saccadic variables
2r2r2r2r2 repeated-measures analyses of variance
(ANOVA) were calculated with drug (placebo, nicotine)
and delay (standard trial, delay trial) as within-subjects
factors and psychosis (patients, controls), smoking
(smokers, non-smokers) and order (nicotine/placebo,
placebo/nicotine) as between-subjects factors. Order was
included as a factor to account for possible practice eﬀects
and possibly unbalanced distribution of patch order
across the subgroups. As our design is a factorial design
with ﬁve factors, each factor having two levels, it is quite
a complex design. Therefore, we present the results for
each saccadic variable (antisaccade errors, antisaccade
latency, prosaccade latency) separately to enhance
readability. Main eﬀects and simple interactions are pre-
sented ﬁrst, followed by the higher-order interactions.
Higher-order interactions (e.g. triple interactions) should
be interpreted with caution as for subgroup analyses the
statistical power is decreased and the risk of ﬁnding
at least one spurious statistically signiﬁcant result is
increased. Finally, we also explored whether perform-
ance change scores (i.e. diﬀerence values : placebo
data – nicotine data) were correlated with neuroleptic
dose (i.e. chlorpromazine equivalents), PANSS scores,
number of cigarettes/d, Fagerstro¨m Test for Nicotine
Dependence (FTND) score and cotinine plasma level
using Pearson’s correlations. Greenhouse–Geisser cor-
rection of p-values was applied when sphericity was
violated. The signiﬁcance level of all statistical tests was
set at p<0.05.
Results
Demographic, clinical and smoking characteristics
A total of 22 patients with psychosis (12 smokers and 10
non-smokers) and 26 controls (14 smokers and 12 non-
smokers) participated in the study. Participants were
matched regarding smoking status, sex, age and parental
socio-economic status (Table 1). However, non-smoking
patients exhibited a higher verbal IQ than smoking
patients (p=0.02) and smoking controls (p=0.01),
whereas non-smoking patients did not diﬀer from non-
smoking controls (p=0.83 ; Bonferroni-corrected post hoc
comparisons). Smoking patients did not diﬀer from
smoking controls regarding pack years. However, smok-
ing patients diﬀered from smoking controls on the
FTND score and patients also tended to smoke more
cigarettes/d than controls (Table 1). Nineteen patients
were diagnosed with schizophrenia, paranoid type
(DSM-IV 295.3) and three were diagnosed with
schizo-aﬀective disorder (DSM-IV 295.7). All patients
were out-patients and received treatment with atypical
antipsychotics (six received quetiapine and/or risper-
idone, 10 received clozapine and/or amisulpride, ﬁve
Table 1. Demographic, clinical and smoking characteristics
Patients (n=22) Controls (n=26)
pSmokers Non-smokers Smokers Non-smokers
n 12 10 14 12 0.96
Sex (m/f) 77/5 5/5 7/7 4/8 0.66
Age (yr) 33.33 (10.72) 37.60 (5.40) 31.29 (8.99) 31.17 (9.82) 0.33
Parental SES 12.34 (1.74) 15.53 (2.99) 14.61 (2.70) 13.81 (2.94) 0.06
Verbal IQ 103.67 (10.62) 121.30 (14.73) 103.57 (10.50) 112.83 (16.34) 0.006
Order of patch (n nicotine
ﬁrst/n placebo ﬁrst)
7/5 6/4 4/10 7/5 0.30
Years of illness 9.33 (8.42) 10.30 (7.30) 0.78
Chlorpromazine equivalents 321.32 (241.40) 731.69 (466.45) 0.03
PANSS positive 11.83 (2.86) 12.10 (1.85) 0.80
PANSS negative 15.17 (7.04) 10.60 (2.91) 0.07
PANSS overall pathology 28.25 (8.97) 27.30 (5.52) 0.77
CDSS 4.75 (4.99) 4.00 (3.40) 0.40
Pack years 14.41 (14.88) 10.67 (6.63) 0.41
FTND score 6.33 (2.71) 3.00 (2.35) 0.003
Cigarettes/d 18.73 (8.45) 13.54 (6.15) 0.09
m, Male ; f, female ; SES, Socioeconomic status ; FTND, Fagerstro¨m Test for Nicotine Dependence ; PANSS, Positive and Negative
Syndrome Scale ; CDSS, Calgary Depression Scale for Schizophrenia.
Data represent means (S.D) unless otherwise speciﬁed.
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received olanzapine and/or aripiprazole, three received
amisulpride and one received ziprasidone). The average
dose of antipsychotic medication was 578.76¡
486.01 mg/d chlorpromazine equivalents (Woods, 2003;
Bazire, 2010) with non-smoking patients receiving on
average a higher dose than smoking patients. Four pa-
tients additionally received the antidepressant citalo-
pram. Patients exhibited low scores of positive and
negative symptoms as well as low scores of overall
pathology and depression (see Table 1).
Cotinine plasma levels
Cotinine data of 44 participants were available. In non-
smoking participants, mean cotinine plasma levels were
signiﬁcantly higher for the nicotine session (16.43¡
7.66 ng/ml) than for the placebo session (0.92¡2.18 ng/
ml; t18=8.66, p<0.001). Likewise, in smoking partici-
pants mean cotinine plasma levels were signiﬁcantly
higher for the nicotine session (167.27¡91.65 ng/ml)
than for the placebo session (94.31¡81.50 ng/ml;
t23=7.72, p<0.001) indicating successful experimental
manipulation.
Antisaccade errors
There was a signiﬁcant main eﬀect of psychosis
(F1,40=5.18, p=0.03, gp2=0.12) indicating that schizo-
phrenia patients made more antisaccade errors
(19.02¡14.02%) than controls (13.79¡10.83%). There
was a signiﬁcant main eﬀect of delay (F1,40=107.36,
p<0.0001, gp2=0.73), but no signiﬁcant psychosisrdelay
interaction (F1,40=2.82, p=0.10, gp2=0.07) : both patients
and controls made fewer antisaccade errors in the
delayed trials than in the standard trials (see Fig. 1 and
Table 2). We did not ﬁnd a main eﬀect of drug (F1,40=1.34,
p=0.25, gp2=0.03), but we found a signiﬁcant
drugrdelay interaction (F1,40=5.56, p=0.02, gp2=0.12)
demonstrating that nicotine decreased antisaccade error
rate in standard trials but not delayed trials (see Fig. 1).
There were no signiﬁcant psychosisrdrug (F1,40=0.54,
p=0.47, gp2=0.01) or psychosisrdrugrdelay (F1,40=1.88,
p=0.18, gp2=0.05) interactions, indicating that nicotine
enhanced antisaccade performance by decreasing anti-
saccade error rate in patients and controls equally. There
was a trend for a main eﬀect of smoking (F1,40=3.03,
p=0.09, gp2=0.07) : smokers tended to make more
antisaccade errors (19.04¡14.28%) than non-smokers
(12.82¡9.89%). There was no smokingrdrug interaction
(F1,40=0.14, p=0.71, gp2=0.004) and there was no signiﬁ-
cant smokingrdrugrdelay interaction (F1,40=2.88,
p=0.10, gp2=0.07) indicating that smoking status did not
inﬂuence the nicotine eﬀect on antisaccade error rate.
There were no main (F1,40=0.0001, p=0.99, gp2<0.0001) or
interaction eﬀects of order (all p>0.18) on antisaccade
error rate. There were no further higher order interac-
tions for antisaccade error rate (all p>0.17).
Antisaccade latency
There was no main eﬀect of psychosis (F1,40=0.63,
p=0.43, gp2=0.02) on antisaccade latency. There was a
signiﬁcant main eﬀect of delay (F1,40=572.14, p<0.0001,
gp
2=0.94) demonstrating that all participants exhibited
lower antisaccade latencies in the delayed trials com-
pared to the standard trials (see Fig. 2 and Table 2). There
was also a trend for a psychosisrdelay interaction
(F1,40=4.21, p=0.05, gp2=0.10) indicating that the con-
trol group beneﬁted to a greater extent from the
delayed condition (diﬀerence standard – delayed trials=
161.32 ms) than the patient group (diﬀerence standard –
delayed trials=135.83 ms). There was a main eﬀect of
drug (F1,40=16.14, p=0.0003, gp2=0.29) : nicotine de-
creased antisaccade latencies (see Fig. 2). No drugr
delay interaction was found (F1,40=0.08, p=0.78,
gp
2=0.002). The psychosisrdrug interaction (F1,40=2.74,
p=0.11, gp2=0.06) was not signiﬁcant. There was no
psychosisrdrugrdelay triple interaction (F1,40=0.18,
p=0.67, gp2=0.005). There was no main eﬀect of
smoking (F1,40=0.63, p=0.43, gp2=0.02), but there was a
signiﬁcant smokingrdelay interaction (F1,40=6.97,
p=0.01, gp2=0.15). Non-smokers beneﬁted from the
delayed condition to a greater extent (diﬀerence
standard – delayed trials=192.61 ms) than smokers
(diﬀerence standard – delayed trials=127.61 ms). The
smokingrdelayrdrug triple interaction tended towards
signiﬁcance (F1,40=3.81, p=0.06, gp2=0.09) : nicotine ten-
ded to decrease antisaccade latencies in the delayed trials
to a greater extent in smokers (diﬀerence placebo –nico-
tine=31.75 ms) than in non-smokers (diﬀerence
placebo – nicotine=7.82 ms). The smokingrdelayr
psychosis triple interaction also tended towards signiﬁ-
cance (F1,40=2.93, p=0.09, gp2=0.07) : non-smoking
40
35
30
25
20
15
10
5
0
Patients Controls
A
nt
is
ac
ca
de
 e
rr
or
s 
(%
)
Placebo standard trials
Placebo delayed trials
Nicotine standard trials
Nicotine delayed trials
Fig. 1. Eﬀects on antisaccade error rate in patients and controls
(means¡S.E.). Schizophrenia patients made signiﬁcantly more
antisaccade errors than controls (main eﬀect of psychosis,
p=0.03). Both patients and controls made fewer antisaccade
errors in the delayed trials than in the standard trials (main eﬀect
of delay, p<0.0001). Nicotine signiﬁcantly reduced antisaccade
error rate in the standard trials, but not in the delayed trials
(drugrdelay interaction, p=0.02).
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schizophrenia patients tended to beneﬁt more from de-
layed trials than smoking patients and the control group.
There was a trend for a main eﬀect of order on
antisaccade latency (F1,40=3.26, p=0.08, gp2=0.07) and
there was a signiﬁcant drugrorder interaction
(F1,40=22.83, p<0.0001, gp2=0.36) indicating that those
participants who received the nicotine patch at session
two exhibited a decreased antisaccade latency. There
were no further higher order interactions for antisaccade
latency (all p>0.76).
Prosaccade latency
There was no main eﬀect of psychosis (F1,40=0.27,
p=0.61, gp2=0.007) indicating that schizophrenia patients
and controls did not diﬀer in prosaccade reaction time.
There was a signiﬁcant main eﬀect of delay (F1,40=87.35,
p<0.0001, gp2=0.69) : prosaccade latencies were shorter in
delayed trials than in standard trials. However, there was
no psychosisrdelay interaction (F1,40=1.62, p=0.21,
gp
2=0.04) indicating that a delay decreased prosaccade
latencies in patients and controls equally. There was no
main eﬀect of drug (F1,40=1.87, p=0.18, gp2=0.05) or
drugrdelay interaction (F1,40=1.13, p=0.30, gp2=0.03).
No main eﬀect of smoking (F1,40=0.88, p=0.35, gp2=0.02)
or smokingrdrug interaction was found (F1,40=0.91,
p=0.34, gp2=0.02). There was a trend for a main eﬀect
of order (F1,40=3.17, p=0.08, gp2=0.07) on prosaccade
latency and there was a signiﬁcant drugrorder interac-
tion (F1,40=11.38, p=0.002, gp2=0.22) indicating that those
participants who received the nicotine patch at session
two showed a decreased prosaccade reaction time. It isT
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Fig. 2. Eﬀects on antisaccade latency in patients and controls
(means¡S.E.). Schizophrenia patients did not diﬀer from
controls regarding antisaccade latency (no main eﬀect of
psychosis, p=0.43). Both patients and controls exhibited shorter
antisaccade latencies in the delayed trials than in the standard
trials (main eﬀect of delay, p<0.0001). Nicotine signiﬁcantly
reduced antisaccade latencies (main eﬀect of drug, p=0.0003),
but there was no drugrdelay interaction (p=0.78). The
drugrpsychosis interaction was not signiﬁcant (p=0.11).
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very likely that this interaction reﬂects a practice eﬀect
from session one to session two. There were no higher
order interactions eﬀects with order (all p>0.32) and no
further higher order interactions were found for pro-
saccade latency (all p>0.78).
Correlations with performance change scores
With the ﬁnding that nicotine decreased antisaccade
error rate in the standard trials, we investigated whether
the level of habitual smoking was related to this eﬀect. In
the entire sample, number of cigarettes/d was not sig-
niﬁcantly correlated with performance change scores
(i.e. placebo – nicotine) of antisaccade error rate in stan-
dard trials (r=0.21, p=0.33). Likewise, there was no such
signiﬁcant correlation in the subsample of patients
(r=0.26, p=0.44) nor in the subsample of controls
(r=0.20, p=0.49). FTND scores also were not correlated
with performance change scores (r=0.09, p=0.67) and
there was no signiﬁcant correlation in either the sub-
sample of patients (r=0.29, p=0.36) or in the
subsample of controls (r=x0.11, p=0.71). In addition,
we evaluated whether performance change score was
related to neuroleptic dose (i.e. chlorpromazine equiva-
lents) and PANSS scores in patients. Chlorpromazine
equivalents were not signiﬁcantly correlated with per-
formance change score (r=0.01, p=0.97). PANSS scores
were also not signiﬁcantly correlated with performance
change score (all r<0.03, all p>0.88). Finally, we tested
whether there was a correlation between cotinine plasma
levels and performance change scores. In the entire
sample, cotinine plasma level was signiﬁcantly positively
correlated with performance change score of antisaccade
error rate in standard trials (r=0.36, p=0.02). This corre-
lation was signiﬁcant in the subsample of patients
(r=0.44, p=0.048), but not in the subsample of controls
(r=0.25, p=0.24).
Discussion
In the present study we replicated the ﬁnding of in-
creased antisaccade error rates in schizophrenia patients
compared to controls indicating worse antisaccade per-
formance in schizophrenia patients. However, we did not
ﬁnd longer antisaccade latencies in schizophrenia
patients. Possibly, this lacking group diﬀerence is due to
the antisaccade task design with intermixed standard and
delayed trials : Reuter et al. (2005) who used a very simi-
lar design also failed to ﬁnd signiﬁcantly longer anti-
saccade latencies in the patient group. Similarly to
Reuter et al. (2005, 2007), we also found a performance-
enhancing eﬀect of delay: both schizophrenia patients
and controls made signiﬁcantly fewer antisaccade
errors and exhibited shorter antisaccade latencies in
the delayed trials than in the standard trials. We also
employed a block of prosaccades as a control condition.
As for the antisaccade condition, we found a signiﬁcant
latency-reducing eﬀect of delay indicating that elongated
ﬁxation also improved prosaccadic eye movements. We
did not ﬁnd any eﬀects of nicotine on prosaccade per-
formance indicating that nicotine speciﬁcally enhanced
performance in the more demanding antisaccade task.
The main focus of the present study was to examine
eﬀects of nicotine on antisaccade performance. The ﬁrst
main ﬁnding was that nicotine improved antisaccade
performance in schizophrenia patients and controls
equally, i.e. we did not ﬁnd interaction eﬀects with psy-
chosis status. Nicotine signiﬁcantly reduced antisaccade
error rates in standard trials, but not in delayed trials.
This error-reducing eﬀect of nicotine replicates ﬁndings
from previous studies in which standard antisaccade
paradigms (i.e. without a temporal delay) were used
(Depatie et al., 2002 ; Larrison-Faucher et al., 2004) and
extends them by suggesting that performance in delayed
antisaccades is not inﬂuenced by nicotine. Possibly,
nicotine selectively enhanced inhibition of reﬂexive sac-
cades in standard trials and did not inﬂuence delayed
trials as the eﬀect of delay may already have supported
inhibition suﬃciently. As the eﬀect of delay was very
pronounced in our study, our participants were probably
already performing at maximum; not allowing further
improvement by nicotine. Thus, future studies are nee-
ded to investigate which component of antisaccade per-
formance (i.e. inhibition or saccade generation) is
enhanced by nicotine.
Furthermore, nicotine reduced antisaccade latencies in
patients and controls regardless of trial type (i.e. trial
with or without delay). Two studies in healthy partici-
pants also demonstrated that nicotine decreased anti-
saccade reaction times (Rycroft et al., 2007 ; Ettinger et al.,
2009), whereas the study by Larrison-Faucher et al. (2004)
merely found a trend for nicotine to reduce antisaccade
latencies and the study by Depatie et al. (2002) did not
ﬁnd an eﬀect of nicotine on antisaccade latency. These
inconsistent results regarding antisaccade latency might
indicate that antisaccade error rate is the parameter
which is more sensitive to the eﬀects of nicotine. In the
present study, we also found a practice eﬀect for anti-
saccade latencies. The signiﬁcant interaction of the factors
drug and order indicated that the subgroup which had
nicotine at session two performed best. It is very likely
that this was due to the combination of a practice eﬀect
from session one to session two and a nicotine eﬀect.
An important ﬁnding is that smoking status did not
inﬂuence nicotine eﬀects on antisaccade performance in-
dicating an equal procognitive eﬀect of nicotine in
smokers and non-smokers. So far, the published studies
on antisaccade performance and nicotine treatment in
schizophrenia patients (Depatie et al., 2002 ; Larrison-
Faucher et al., 2004) only tested participants who
were smokers. Therefore, our results favour a genuine
nicotine eﬀect instead of a simple relief-from-withdrawal
phenomenon. A study by Ettinger et al. (2009) in healthy
participants administered nicotine and placebo on two
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separate occasions and tested light-to-moderate smokers
and non-smokers with the antisaccade task. Nicotine
signiﬁcantly reduced antisaccade latencies both in smo-
kers and in non-smokers (Ettinger et al., 2009). In ad-
dition, the amount of the nicotine-induced reduction in
antisaccade latency in smokers was comparable to the
reduction in antisaccade latency caused by nicotine in
non-smokers (Ettinger et al., 2009). The results of Ettinger
et al. (2009) also support the idea that nicotine is eﬀective
in improving antisaccade performance both in smokers
and non-smokers. Finally, the clinical trial by Hong et al.
(2011) demonstrated that the a4b2 nAChR agonist var-
enicline reduced antisaccade error rate in patients with
schizophrenia regardless of smoking status. The results
of Hong et al. (2011) further underline the notion of a
genuine procognitive eﬀect of cholinergic modulation on
antisaccade performance.
Limitations of the present study include the relatively
small sample size and the fact that the smoking partici-
pants were deprived of smoking (overnight abstinence)
when they received nicotine treatment. This feature of
the design makes it diﬃcult to disentangle genuine
nicotine eﬀects from relief-from-withdrawal in the sub-
sample of smoking participants. Therefore, future studies
might want to opt for a minimum amount of deprivation
such as 2 h as suggested by Heishman et al. (2010).
Furthermore, future studies should assess withdrawal
symptoms, e.g. with the Cigarette Withdrawal Scale
(Etter, 2005).
In conclusion, the present ﬁndings indicate that
beneﬁcial eﬀects of nicotine on antisaccade performance
are not conﬁned to smoking schizophrenia patients.
Rather, the present results suggest an equal procognitive
eﬀect of nicotine on antisaccade error rate in smokers and
non-smokers. More generally, the present study suggests
that the antisaccade paradigm is well suited as a neuro-
cognitive biomarker for the investigation of the eﬀec-
tiveness of cholinergic substances in future clinical trials.
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